Logotype for PolyPid Ltd

PolyPid (PYPD) investor relations material

PolyPid Q3 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for PolyPid Ltd
Q3 2025 earnings summary12 Nov, 2025

Executive summary

  • Pre-NDA meeting with FDA for D-PLEX100 scheduled for early December, aiming for NDA submission in early 2026 leveraging fast track and breakthrough therapy designations.

  • European marketing authorization application preparation underway, following successful Israeli Ministry of Health GMP inspection.

  • Strategic partnership discussions in the U.S. progressing, supported by positive SHIELD II phase III trial results.

  • Achieved commercial manufacturing readiness milestone with successful IMOH GMP inspection.

  • Market access study confirms strong interest and commercial potential for D-PLEX100 among surgeons and hospital pharmacy directors.

Financial highlights

  • Q3 2025 R&D expenses were $5.3M, down from $6.2M in Q2 2025 and $6M in Q3 2024, reflecting SHIELD II trial completion.

  • General and administrative expenses rose to $1.8M from $1.2M in Q3 2024; marketing and business development expenses increased to $0.4M from $0.2M.

  • Net loss for Q3 2025 was $7.5M ($0.37/share), improved from $7.8M ($1.22/share) in Q3 2024.

  • For the nine months ended September 30, 2025, net loss was $25.7M ($1.72/share) vs. $20.5M ($3.82/share) in 2024.

  • Cash, cash equivalents, and short-term deposits totaled $18.8M as of September 30, 2025, up from $15.6M at year-end 2024.

Outlook and guidance

  • NDA submission for D-PLEX100 expected in early 2026, with rolling submission planned post-December FDA meeting.

  • Current cash balance expected to fund operations well into 2026.

  • Ongoing evaluation of manufacturing expansion to address U.S. local production trends and future peak sales.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next PolyPid earnings date

Logotype for PolyPid Ltd
Q4 202511 Feb, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next PolyPid earnings date

Logotype for PolyPid Ltd
Q4 202511 Feb, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

PolyPid Ltd. is a late-stage biopharmaceutical company focused on enhancing surgical outcomes through innovative drug delivery systems. The company's proprietary PLEX (Polymer-Lipid Encapsulation Matrix) technology is designed to enable localized, prolonged, and controlled release of active pharmaceutical ingredients at the surgical site. This technology aims to optimize therapeutic efficacy and minimize side effects by maintaining a consistent drug presence over an extended period. The company is headquartered in Petach Tikva, Israel, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage